Cephalexin in lower respiratory tract infections

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Medicine

Background:

• Cephalexin has a 12-year history of clinical use for respiratory and other infections.
• It demonstrates reliable gastrointestinal absorption and achieves therapeutic serum and tissue levels with minimal toxicity.

Purpose of the Study:

• To evaluate the clinical utility of cephalexin in managing respiratory tract infections.
• To identify pathogens susceptible and resistant to cephalexin, particularly in the context of community-acquired lower respiratory tract infections.

Main Methods:

• Review of clinical usage data and antimicrobial spectrum of cephalexin.
• Analysis of cephalexin's efficacy against common respiratory pathogens, including Haemophilus influenzae.

Main Results:

• Cephalexin covers most pathogens causing community-acquired lower respiratory tract infections, excluding Haemophilus influenzae.
• Resistance in H. influenzae limits its use in pediatric populations and some adult chronic bronchitis exacerbations.
• It is highly effective for adult lower respiratory tract infections, serving as a primary, alternative, or continuation therapy.

Conclusions:

• Cephalexin is a valuable agent for adult lower respiratory tract infections, with notable limitations against H. influenzae.
• Clinical decisions should consider pathogen susceptibility and patient population, especially in pediatric cases.
• Cerebrospinal fluid penetration is minimal, necessitating caution when meningitis is suspected in patients with respiratory infections.